These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27838511)

  • 21. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacotherapy of hyperglycemia.
    Kulasa KM; Henry RR
    Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol.
    Lo MC; Lansang MC
    Am J Ther; 2013; 20(6):638-53. PubMed ID: 20838206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diabetes mellitus: new drugs for a new epidemic.
    Nicholson G; Hall GM
    Br J Anaesth; 2011 Jul; 107(1):65-73. PubMed ID: 21610015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse effects and safety of SGLT-2 inhibitors.
    Halimi S; Vergès B
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S28-34. PubMed ID: 25554069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhaled human [rDNA origin] insulin, a novel formulation for diabetes mellitus.
    Pham DQ; Cohen H; Chu V
    J Clin Pharmacol; 2007 Jul; 47(7):890-903. PubMed ID: 17585117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience.
    Deol H; Lekkakou L; Viswanath AK; Pappachan JM
    Endocrine; 2017 Jan; 55(1):173-178. PubMed ID: 27696231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
    Balakumar P; Dhanaraj SA
    Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016; 9(3):409-18. PubMed ID: 26732230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients: Revision of Literature and Personal Considerations.
    Elena C; Chiara M; Angelica B; Chiara MA; Laura N; Chiara C; Claudio C; Antonella F; Nicola G
    Curr Pharm Biotechnol; 2018; 19(15):1210-1220. PubMed ID: 30605054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological Intervention in Type 2 Diabetes Mellitus - A Pathophysiologically Reasoned Approach?
    Forst T; Heise T; Plum-Morschel L
    Curr Diabetes Rev; 2016; 12(4):429-439. PubMed ID: 27296043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update.
    Kumar A; Mazumder R; Rani A; Pandey P; Khurana N
    Curr Diabetes Rev; 2024; 20(4):e051023221768. PubMed ID: 37888820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions.
    Amin M; Suksomboon N
    Drug Saf; 2014 Nov; 37(11):903-19. PubMed ID: 25249046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic molecules against type 2 diabetes: What we have and what are we expecting?
    Kumar A; Bharti SK; Kumar A
    Pharmacol Rep; 2017 Oct; 69(5):959-970. PubMed ID: 28822958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus.
    Akhlaghi F; Matson KL; Mohammadpour AH; Kelly M; Karimani A
    Clin Pharmacokinet; 2017 Jun; 56(6):561-571. PubMed ID: 27832452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.